GSK plc announced that the US Food and Drug Administration has approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option.
- Read more about USFDA approves Menveo in a new single-vial presentation
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/usfda-approves-menveo-in-a-new-single-vial-presentation
No comments:
Post a Comment